Trial Profile
A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2021
Price :
$35
*
At a glance
- Drugs Oxycodegol (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors Nektar Therapeutics
- 26 Sep 2013 Primary endpoint 'Pain-score' has not been met, according to Nektar Therapeutic media release.
- 26 Sep 2013 Preliminary top-line results announced in a Nektar Therapeutic media release.
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.